IL17A and psoriasis vulgaris: Accordingly, secukinumab (anti-IL-17 monoclonal antibody) has been approved as a first-line treatment for the management of moderate-to-severe plaque psoriasis [78] and as a second-line treatment for psoriatic arthritis.